









市场行情
/
股票
/
nasdaq-bcyc
/

Bicycle Therapeutics PLC

BCYC

6.940USD

-0.250-3.48%

交易中（美东）报价延迟15分钟

346.09M总市值

亏损市盈率 TTM



Bicycle Therapeutics PLC

6.940

-0.250-3.48%

概览公司财务分析

概览

公司

财务

分析

关于 Bicycle Therapeutics PLC 公司

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.

Bicycle Therapeutics PLC简介



公司代码BCYC

公司名称Bicycle Therapeutics PLC

上市日期May 23, 2019

CEOLee (Kevin)

员工数量305

证券类型Depository Receipt

年结日May 23

公司地址Blocks A & B, Portway Building

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United Kingdom

邮编CB21 6GS

电话11441223261503

网址https://www.bicycletherapeutics.com/

公司代码BCYC

上市日期May 23, 2019

CEOLee (Kevin)

Bicycle Therapeutics PLC公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Kevin Lee, Ph.D.

Chief Executive Officer, Executive Director

275.59K

-23.43%

Dr. Michael Skynner, Ph.D.

Chief Technology Officer

72.92K

+73.03%

Mr. Alistair Milnes

Chief Operating Officer

25.33K

-65.69%

Ms. Janice Bourque

Non-Executive Independent Director

18.31K

+49.49%

Charles Swanton

Independent Director

Dr. Roger D. Dansey, M.D.

Independent Director

Mr. Herve Hoppenot

Independent Director

Mr. Eric Westin, M.D.

Chief Medical Officer

Dr. Alessandro Riva, M.D.

Non-Executive Independent Director

Mr. Stephen Sands

Non-Executive Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Kevin Lee, Ph.D.

Chief Executive Officer, Executive Director

275.59K

-23.43%

Dr. Michael Skynner, Ph.D.

Chief Technology Officer

72.92K

+73.03%

Mr. Alistair Milnes

Chief Operating Officer

25.33K

-65.69%

Ms. Janice Bourque

Non-Executive Independent Director

18.31K

+49.49%

Charles Swanton

Independent Director

Dr. Roger D. Dansey, M.D.

Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Baker Bros. Advisors LP

21.80%

Forbion Capital Partners

6.91%

Armistice Capital LLC

5.96%

Westfield Capital Management Company, L.P.

5.91%

Invus Public Equities Advisors, LLC

4.03%

其他

55.38%

持股股东

占比

Baker Bros. Advisors LP

21.80%

Forbion Capital Partners

6.91%

Armistice Capital LLC

5.96%

Westfield Capital Management Company, L.P.

5.91%

Invus Public Equities Advisors, LLC

4.03%

其他

55.38%

股东类型

持股股东

占比

Hedge Fund

37.45%

Investment Advisor

15.62%

Investment Advisor/Hedge Fund

14.44%

Venture Capital

7.08%

Research Firm

3.61%

Individual Investor

1.59%

Pension Fund

0.49%

Family Office

0.25%

其他

19.47%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

242

39.22M

114.58%

+31.05K

2025Q3

266

40.06M

126.53%

-4.18M

2025Q2

264

44.22M

123.05%

-338.39K

2025Q1

249

44.93M

127.83%

-16.05M

2024Q4

249

44.97M

130.44%

+273.71K

2024Q3

245

43.83M

123.27%

+876.01K

2024Q2

237

43.44M

106.75%

+5.72M

2024Q1

253

34.16M

113.53%

-14.25M

2023Q4

258

34.56M

124.36%

-3.64M

2023Q3

255

38.68M

90.77%

+8.35M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Baker Bros. Advisors LP

10.89M

21.83%

Jun 30, 2025

Forbion Capital Partners

3.45M

6.92%

Jun 30, 2025

Armistice Capital LLC

2.80M

5.61%

+128.00K

+4.79%

Jun 30, 2025

Westfield Capital Management Company, L.P.

2.78M

5.58%

+123.19K

+4.64%

Jun 30, 2025

Invus Public Equities Advisors, LLC

2.01M

4.04%

+200.00K

+11.03%

Jun 30, 2025

Long Focus Capital Management LLC

1.32M

2.64%

+23.54K

+1.82%

Jun 30, 2025

T. Rowe Price Associates, Inc.

1.47M

2.94%

-68.19K

-4.44%

Jun 30, 2025

Candriam Luxembourg S.A.

1.32M

2.65%

Aug 31, 2025

Acadian Asset Management LLC

698.50K

1.4%

+572.44K

+454.09%

Jun 30, 2025

Candriam Belgium S.A.

1.17M

2.35%

-32.82K

-2.72%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Virtus LifeSci Biotech Clinical Trials ETF

0.63%

Invesco NASDAQ Future Gen 200 ETF

0.59%

Harbor Health Care ETF

0.23%

ALPS Medical Breakthroughs ETF

0.17%

iShares Health Innovation Active ETF

0.05%

Invesco Nasdaq Biotechnology ETF

0.04%

ProShares Ultra Nasdaq Biotechnology

0.04%

SPDR S&P International Small Cap ETF

0.03%

iShares Biotechnology ETF

0.02%

ActivePassive International Equity ETF

Virtus LifeSci Biotech Clinical Trials ETF

占比0.63%

Invesco NASDAQ Future Gen 200 ETF

占比0.59%

Harbor Health Care ETF

占比0.23%

ALPS Medical Breakthroughs ETF

占比0.17%

iShares Health Innovation Active ETF

占比0.05%

Invesco Nasdaq Biotechnology ETF

占比0.04%

ProShares Ultra Nasdaq Biotechnology

占比0.04%

SPDR S&P International Small Cap ETF

占比0.03%

iShares Biotechnology ETF

占比0.02%

ActivePassive International Equity ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Bicycle Therapeutics PLC的前五大股东是谁？



Bicycle Therapeutics PLC 的前五大股东如下：
Baker Bros. Advisors LP持有股份：10.89M，占总股份比例：21.83%。
Forbion Capital Partners持有股份：3.45M，占总股份比例：6.92%。
Armistice Capital LLC持有股份：2.80M，占总股份比例：5.61%。
Westfield Capital Management Company, L.P.持有股份：2.78M，占总股份比例：5.58%。
Invus Public Equities Advisors, LLC持有股份：2.01M，占总股份比例：4.04%。